<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS" code="L01XA" /></DRUG1>
<DRUG2>
<CLASS name="AMINOGLYCOSIDES" code="J01GB-001" /></DRUG2>
<DESCRIPTION>Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS" code="L01XA" /></DRUG1>
<DRUG2>
<CLASS name="LOOP DIURETICS" code="C03CA-001" /></DRUG2>
<DESCRIPTION>Risk of addition of the ototoxic and/or nephrotoxic effects</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
